Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Depreciation & Amortization (CF) (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Depreciation & Amortization (CF) for 4 consecutive years, with $36000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Depreciation & Amortization (CF) fell 97.07% year-over-year to $36000.0, compared with a TTM value of $3.2 million through Sep 2025, down 38.58%, and an annual FY2024 reading of $5.1 million, up 4.6% over the prior year.
  • Depreciation & Amortization (CF) was $36000.0 for Q3 2025 at Atara Biotherapeutics, down from $236000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $1.8 million in Q1 2025 and bottomed at $36000.0 in Q3 2025.
  • Average Depreciation & Amortization (CF) over 4 years is $1.2 million, with a median of $1.2 million recorded in 2024.
  • Peak annual rise in Depreciation & Amortization (CF) hit 29.04% in 2025, while the deepest fall reached 97.07% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $1.3 million in 2022, then dropped by 3.98% to $1.2 million in 2023, then fell by 8.71% to $1.1 million in 2024, then plummeted by 96.73% to $36000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for ATRA at $36000.0 in Q3 2025, $236000.0 in Q2 2025, and $1.8 million in Q1 2025.